Novel Strategies for Improving Outcomes in Pediatrics with Uncontrolled Moderate-to-Severe Asthma

Released On
October 15, 2021

Expires On
October 14, 2022

Media Type

Completion Time
60 minutes

Allergy & Immunology, Pediatrics, Primary Care

Asthma, Pediatrics

Scroll to the Bottom of this Information to Begin this Course




This activity is provided by Horizon CME.

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of physicians and other clinicians who work in pediatric pulmonology, allergy, immunology, respiratory, and primary care/internal medicine. This will include (MD/DOs), nurse practitioners (NPs) and physician assistants (PAs) who manage pediatric patients with asthma.

Program Overview

Asthma is one of the most common chronic conditions in the pediatric population, and although existing medications can reduce symptoms, management is still suboptimal. Increased understanding of the pathophysiology of asthma has resulted in novel biologic therapies targeted towards molecules involved in the type 2 inflammatory signaling cascade associated with asthma.

In this roundtable discussion, expert faculty discuss the role of type 2 inflammation in the pathology of asthma, biologic therapies and their role in the treatment of asthma in children and adolescents, and strategies for effective communication with patients and caregivers for optimzing treatment of patients with moderate to severe asthma.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the pathophysiology of type 2 inflammation in asthma
  • Discuss the role of biologics in the treatment of asthma with type 2 inflammation markers
  • Formulate treatment plans to manage moderate-to-severe asthma in pediatric patients
  • Identify strategies for effectively communicating with patients to optimize outcomes in uncontrolled asthma




Jonathan Corren MD

Associate Clinical Professor of Medicine and Pediatrics
David Geffen School of Medicine at UCLA
Los Angeles, CA




Lawrence D. Sher MD

Peninsula Research Associates
Medical Director
Rolling Hills East, CA


Tyler Yates MD

Assistant Professor of Pediatrics
Oregon Health and Sciences University
Portland, OR


Accreditation Statement

Horizon CME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Horizon CME designates this enduring material for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Disclosures of Conflicts of Interest


Jonathan Corren MD

  • Clinical Research Consultant: AstraZeneca, Genentech, Sanofi
  • Advisory Board: AstraZeneca, Genentech, Sanofi
  • Speakers Bureau : AstraZeneca, Genentech, Sanofi


Lawrence D. Sher MD

  • Research Funding : Regeneron/Sanofi


Tyler Yates MD has no relevant financial relationships to disclose with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

*Horizon CME has mitigated and resolved all relevant financial relationships


Those involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Other Contributors

All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no relevant financial relationships with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Score 75% or higher on the post-test
  4. Submit the evaluation form.
Certificates will be emailed to the participant.


Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Copyright Information

Copyright © 2021 by Horizon CME. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Horizon CME.

Disclosure of Unlabeled Use

Horizon CME requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. This activity will include discussions of off-label treatments not approved by the FDA for use in the United States.


This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact Information

For CME questions please contact: